193 related articles for article (PubMed ID: 19234060)
1. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
[TBL] [Abstract][Full Text] [Related]
2. Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
Quarta A; Melpignano A; Quarta G
Acta Haematol; 2011; 125(4):219-21. PubMed ID: 21266801
[TBL] [Abstract][Full Text] [Related]
3. Conditional disruption of mouse HFE2 gene: maintenance of systemic iron homeostasis requires hepatic but not skeletal muscle hemojuvelin.
Gkouvatsos K; Wagner J; Papanikolaou G; Sebastiani G; Pantopoulos K
Hepatology; 2011 Nov; 54(5):1800-7. PubMed ID: 21748766
[TBL] [Abstract][Full Text] [Related]
4. A high-fat diet modulates iron metabolism but does not promote liver fibrosis in hemochromatotic Hjv⁻/⁻ mice.
Padda RS; Gkouvatsos K; Guido M; Mui J; Vali H; Pantopoulos K
Am J Physiol Gastrointest Liver Physiol; 2015 Feb; 308(4):G251-61. PubMed ID: 25501544
[TBL] [Abstract][Full Text] [Related]
5. HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox.
Santos PC; Cançado RD; Pereira AC; Chiattone CS; Krieger JE; Guerra-Shinohara EM
Acta Haematol; 2010; 124(4):204-5. PubMed ID: 21071928
[No Abstract] [Full Text] [Related]
6. Deferasirox (Exjade) for the treatment of iron overload.
Cappellini MD; Taher A
Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
[TBL] [Abstract][Full Text] [Related]
7. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
8. Exjade (ICL 670): A new oral iron chelator.
Agarwal MB
J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
[TBL] [Abstract][Full Text] [Related]
9. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
Phatak P; Brissot P; Wurster M; Adams PC; Bonkovsky HL; Gross J; Malfertheiner P; McLaren GD; Niederau C; Piperno A; Powell LW; Russo MW; Stoelzel U; Stremmel W; Griffel L; Lynch N; Zhang Y; Pietrangelo A
Hepatology; 2010 Nov; 52(5):1671-779. PubMed ID: 20814896
[TBL] [Abstract][Full Text] [Related]
10. Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia.
Nagler M; Gregor M; Wuillemin WA
Acta Haematol; 2011; 126(2):119-21. PubMed ID: 21659727
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.
Cançado R; Melo MR; de Moraes Bastos R; Santos PC; Guerra-Shinohara EM; Chiattone C; Ballas SK
Eur J Haematol; 2015 Dec; 95(6):545-50. PubMed ID: 25684349
[TBL] [Abstract][Full Text] [Related]
12. Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function.
Maeda T; Nakamaki T; Saito B; Nakashima H; Ariizumi H; Yanagisawa K; Hattori A; Tatsumi Y; Hayashi H; Suzuki K; Tomoyasu S
Eur J Haematol; 2011 Nov; 87(5):467-9. PubMed ID: 21848699
[No Abstract] [Full Text] [Related]
13. Dose titration of deferasirox iron chelation therapy by magnetic resonance imaging for chronic iron storage disease in three adult red bald-headed uakari (Cacajao calvus rubicundus).
Brewer C; Tyszka JM; Stadler CK; Garner M; Baer J; Wood JC
J Zoo Wildl Med; 2014 Jun; 45(2):339-49. PubMed ID: 25000696
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
[TBL] [Abstract][Full Text] [Related]
16. Iron chelation with deferasirox in a patient with de-novo ferroportin mutation.
Unal S; Piperno A; Gumruk F
J Trace Elem Med Biol; 2015 Apr; 30():1-3. PubMed ID: 25744502
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox for transfusion-related iron overload: a clinical review.
Lindsey WT; Olin BR
Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.
Arvapalli RK; Paturi S; Laurino JP; Katta A; Kakarla SK; Gadde MK; Wu M; Rice KM; Walker EM; Wehner P; Blough ER
Cardiovasc Toxicol; 2010 Jun; 10(2):108-16. PubMed ID: 20229123
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox: the new oral iron chelator.
Dubey AP; Sudha S; Parakh A
Indian Pediatr; 2007 Aug; 44(8):603-7. PubMed ID: 17827637
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
Wood JC; Otto-Duessel M; Gonzalez I; Aguilar MI; Shimada H; Nick H; Nelson M; Moats R
Transl Res; 2006 Nov; 148(5):272-80. PubMed ID: 17145573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
